Bio-Rad Laboratories, Inc. (BIO.B)
NYSE: BIO.B · Real-Time Price · USD
396.17
0.00 (0.00%)
Aug 26, 2026, 4:00 PM EDT - Market closed
Bio-Rad Laboratories Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,589 | 2,583 | 2,567 | 2,671 | 2,802 | 2,923 | |
Revenue Growth | 1.37% | 0.65% | -3.92% | -4.67% | -4.12% | 14.81% |
Cost of Revenue | 1,242 | 1,240 | 1,173 | 1,240 | 1,235 | 1,259 |
Gross Profit | 1,348 | 1,344 | 1,394 | 1,431 | 1,567 | 1,663 |
Selling, General & Admin | 827.5 | 819.8 | 810.2 | 824.2 | 827.8 | 851.02 |
Research & Development | 247.7 | 257.6 | 294.3 | 240.9 | 256.9 | 247.34 |
Operating Expenses | 1,075 | 1,077 | 1,105 | 1,065 | 1,085 | 1,098 |
Operating Income | 272.3 | 266.2 | 289.2 | 365.7 | 482.6 | 564.74 |
Interest Expense | -48.8 | -49 | -48.9 | -49.4 | -38.1 | -1.55 |
Interest & Investment Income | 87.9 | 95.5 | 82 | 100.9 | 58.1 | 18.9 |
Currency Exchange Gain (Loss) | 7.6 | 6.6 | 3.9 | 7.3 | 0.2 | -2.75 |
Other Non Operating Income (Expenses) | -0.2 | -0.3 | 3.2 | 4.9 | -5.2 | 0.68 |
EBT Excluding Unusual Items | 318.8 | 319 | 329.4 | 429.4 | 497.6 | 580.01 |
Merger & Restructuring Charges | -46.1 | -46.1 | -21.8 | -27.9 | - | -64.4 |
Gain (Loss) on Sale of Investments | 250.5 | 895.4 | -2,650 | -1,252 | -5,203 | 4,933 |
Gain (Loss) on Sale of Assets | - | - | - | - | 1.4 | - |
Asset Writedown | -172.8 | -172.8 | - | - | - | - |
Pretax Income | 350.4 | 995.5 | -2,343 | -850.1 | -4,704 | 5,449 |
Income Tax Expense | 128 | 235.6 | -498.3 | -212.8 | -1,077 | 1,195 |
Net Income | 222.4 | 759.9 | -1,844 | -637.3 | -3,628 | 4,254 |
Net Income to Common | 222.4 | 759.9 | -1,844 | -637.3 | -3,628 | 4,254 |
Net Income Growth | -30.33% | - | - | - | - | 11.54% |
Shares Outstanding (Basic) | 27 | 27 | 28 | 29 | 30 | 30 |
Shares Outstanding (Diluted) | 27 | 27 | 28 | 29 | 30 | 30 |
Shares Change | -3.11% | -3.31% | -3.41% | -1.93% | -1.40% | 0.16% |
EPS (Basic) | 8.26 | 27.85 | -65.36 | -21.82 | -121.79 | 142.61 |
EPS (Diluted) | 8.26 | 27.85 | -65.36 | -21.82 | -121.79 | 140.83 |
EPS Growth | -28.17% | - | - | - | - | 11.35% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 353.1 | 374.6 | 289.6 | 218.2 | 81.6 | 535.75 |
Free Cash Flow Per Share | 13.12 | 13.73 | 10.26 | 7.47 | 2.74 | 17.74 |
Gross Margin | 52.04% | 52.01% | 54.30% | 53.56% | 55.93% | 56.91% |
Operating Margin | 10.52% | 10.30% | 11.27% | 13.69% | 17.22% | 19.32% |
Profit Margin | 8.59% | 29.42% | -71.86% | -23.86% | -129.45% | 145.57% |
Free Cash Flow Margin | 13.64% | 14.50% | 11.28% | 8.17% | 2.91% | 18.33% |
EBITDA | 441 | 431.6 | 440.8 | 511.6 | 619.9 | 702.34 |
EBITDA Margin | 17.03% | 16.71% | 17.18% | 19.15% | 22.12% | 24.03% |
D&A For EBITDA | 168.7 | 165.4 | 151.6 | 145.9 | 137.3 | 137.6 |
EBIT | 272.3 | 266.2 | 289.2 | 365.7 | 482.6 | 564.74 |
EBIT Margin | 10.52% | 10.30% | 11.27% | 13.69% | 17.22% | 19.32% |
Effective Tax Rate | 36.53% | 23.67% | - | - | - | 21.93% |